A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Part of paid clinical trials in Athens, Georgia.

Sponsor
Bristol-Myers Squibb
Study ID
NCT07680764
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
  • Metastatic Non-Small Cell Lung Cancer (NSCLC)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Pumitamig — DRUG
    Specified dose on specified days
  • Imzokitug — DRUG
    Specified dose on specified days

Study Details

The purpose of this study is to assess the safety, tolerability, and efficacy of Imzokitug in combination with Pumitamig and Platinum-Doublet Chemotherapy (PDCT) versus Pumitamig and PDCT as first-line treatment for participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Key Dates

First listed
Jul 2, 2026
Start date
Aug 15, 2026
Status verified
Jul 2026
Primary completion
Sep 15, 2028
Completion
Sep 15, 2030

Study Design

Enrollment
160 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Arm A
  • Experimental: Arm B
  • Experimental: Arm C
  • Experimental: Arm D

Primary Outcome Measure

Objective response rate (ORR) by investigator (per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1) [ Time Frame: Up to approximately 4 years ]

Central Contacts

  • BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
    855-907-3286
    [email protected]
  • First line of the email MUST contain NCT # and Site #.

Locations (11)

FacilityCityStateZIPSite coordinators
Local Institution - 0170AthensGeorgia30607
Site 0170
Local Institution - 0034LexingtonKentucky40503
Site 0034
Local Institution - 0171LexingtonKentucky40509
Site 0171
Local Institution - 0123BaltimoreMaryland21224
Site 0123
Local Institution - 0180HattiesburgMississippi39401
Site 0180
Nebraska Cancer SpecialistsGrand IslandNebraska68803
Joel Michalski, Site 0172
402-955-2691
Oncology Hematology West PCOmahaNebraska68130
Joel Michalski, Site 0102
402-955-2691
Local Institution - 0080New YorkNew York10021
Site 0080
Local Institution - 0105NashvilleTennessee37212
Site 0105
Local Institution - 0095HoustonTexas77030
Site 0095
Local Institution - 0135MadisonWisconsin53792
Site 0135

Find similar trials in Athens, GA

By research site
Local Institution - 0170· Athens, GALocal Institution - 0034· Lexington, KYLocal Institution - 0171· Lexington, KYLocal Institution - 0123· Baltimore, MDLocal Institution - 0180· Hattiesburg, MSNebraska Cancer Specialists· Grand Island, NE